123 related articles for article (PubMed ID: 16132372)
1. TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: surgical experience and long-term follow-up.
McLoughlin JM; McCarty TM; Cunningham C; Clark V; Senzer N; Nemunaitis J; Kuhn JA
Ann Surg Oncol; 2005 Oct; 12(10):825-30. PubMed ID: 16132372
[TBL] [Abstract][Full Text] [Related]
2. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors.
Senzer N; Mani S; Rosemurgy A; Nemunaitis J; Cunningham C; Guha C; Bayol N; Gillen M; Chu K; Rasmussen C; Rasmussen H; Kufe D; Weichselbaum R; Hanna N
J Clin Oncol; 2004 Feb; 22(4):592-601. PubMed ID: 14726502
[TBL] [Abstract][Full Text] [Related]
3. TNFerade Biologic: preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene.
Rasmussen H; Rasmussen C; Lempicki M; Durham R; Brough D; King CR; Weichselbaum R
Cancer Gene Ther; 2002 Nov; 9(11):951-7. PubMed ID: 12386834
[TBL] [Abstract][Full Text] [Related]
4. A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities.
Mundt AJ; Vijayakumar S; Nemunaitis J; Sandler A; Schwartz H; Hanna N; Peabody T; Senzer N; Chu K; Rasmussen CS; Kessler PD; Rasmussen HS; Warso M; Kufe DW; Gupta TD; Weichselbaum RR
Clin Cancer Res; 2004 Sep; 10(17):5747-53. PubMed ID: 15355902
[TBL] [Abstract][Full Text] [Related]
5. Ionizing radiation: a genetic switch for cancer therapy.
Mezhir JJ; Smith KD; Posner MC; Senzer N; Yamini B; Kufe DW; Weichselbaum RR
Cancer Gene Ther; 2006 Jan; 13(1):1-6. PubMed ID: 16082378
[TBL] [Abstract][Full Text] [Related]
6. Translation of the radio- and chemo-inducible TNFerade vector to the treatment of human cancers.
Weichselbaum RR; Kufe D
Cancer Gene Ther; 2009 Aug; 16(8):609-19. PubMed ID: 19444302
[TBL] [Abstract][Full Text] [Related]
7. Surgical resection after TNFerade therapy for locally advanced pancreatic cancer.
Chadha MK; Litwin A; Levea C; Iyer R; Yang G; Javle M; Gibbs JF
JOP; 2009 Sep; 10(5):535-8. PubMed ID: 19734632
[TBL] [Abstract][Full Text] [Related]
8. Phase I dose-escalation study of tumor necrosis factor-alpha and concomitant radiation therapy.
Hallahan DE; Vokes EE; Rubin SJ; O'Brien S; Samuels B; Vijaykumar S; Kufe DW; Phillips R; Weichselbaum RR
Cancer J Sci Am; 1995; 1(3):204-9. PubMed ID: 9166477
[TBL] [Abstract][Full Text] [Related]
9. Respective roles of TNF-alpha and IL-6 in the immune response-elicited by adenovirus-mediated gene transfer in mice.
Benihoud K; Esselin S; Descamps D; Jullienne B; Salone B; Bobé P; Bonardelle D; Connault E; Opolon P; Saggio I; Perricaudet M
Gene Ther; 2007 Mar; 14(6):533-44. PubMed ID: 17109009
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients.
Tong AW; Nemunaitis J; Su D; Zhang Y; Cunningham C; Senzer N; Netto G; Rich D; Mhashilkar A; Parker K; Coffee K; Ramesh R; Ekmekcioglu S; Grimm EA; van Wart Hood J; Merritt J; Chada S
Mol Ther; 2005 Jan; 11(1):160-72. PubMed ID: 15585417
[TBL] [Abstract][Full Text] [Related]
11. Local delivery of a recombinant adenoassociated vector containing a tumour necrosis factor alpha antagonist gene in inflammatory arthritis: a phase 1 dose-escalation safety and tolerability study.
Mease PJ; Hobbs K; Chalmers A; El-Gabalawy H; Bookman A; Keystone E; Furst DE; Anklesaria P; Heald AE
Ann Rheum Dis; 2009 Aug; 68(8):1247-54. PubMed ID: 18678578
[TBL] [Abstract][Full Text] [Related]
12. Transgene expression of alpha tumor necrosis factor with mutations D142N and A144R under control of human telomerase reverse transcriptase promoter eradicates well-established tumors and induces long-term antitumor immunity.
Xiang J; Munegowda MA; Deng Y
Cancer Gene Ther; 2009 May; 16(5):430-8. PubMed ID: 19096444
[TBL] [Abstract][Full Text] [Related]
13. Technology evaluation: TNFerade, GenVec.
Kircheis R; Wagner E
Curr Opin Mol Ther; 2003 Aug; 5(4):437-47. PubMed ID: 14513689
[TBL] [Abstract][Full Text] [Related]
14. Role for the double-stranded RNA-activated protein kinase PKR in Ad-TNF-alpha gene therapy in esophageal cancer.
von Holzen U; Bocangel D; Pataer A; Vorburger SA; Liu Y; Lu X; Hunt KK; Swisher SG
Surgery; 2005 Aug; 138(2):261-8. PubMed ID: 16153435
[TBL] [Abstract][Full Text] [Related]
15. Local gene delivery of tumor necrosis factor alpha can impact primary tumor growth and metastases through a host-mediated response.
MacGill RS; Davis TA; Macko J; Mauceri HJ; Weichselbaum RR; King CR
Clin Exp Metastasis; 2007; 24(7):521-31. PubMed ID: 17653822
[TBL] [Abstract][Full Text] [Related]
16. Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer.
Palmer DH; Mautner V; Mirza D; Oliff S; Gerritsen W; van der Sijp JR; Hubscher S; Reynolds G; Bonney S; Rajaratnam R; Hull D; Horne M; Ellis J; Mountain A; Hill S; Harris PA; Searle PF; Young LS; James ND; Kerr DJ
J Clin Oncol; 2004 May; 22(9):1546-52. PubMed ID: 15051757
[TBL] [Abstract][Full Text] [Related]
17. Synthetic anticancer gene medicine exploits intrinsic antitumor activity of cationic vector to cure established tumors.
Dufès C; Keith WN; Bilsland A; Proutski I; Uchegbu IF; Schätzlein AG
Cancer Res; 2005 Sep; 65(18):8079-84. PubMed ID: 16166279
[TBL] [Abstract][Full Text] [Related]
18. Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study.
Cunningham CC; Chada S; Merritt JA; Tong A; Senzer N; Zhang Y; Mhashilkar A; Parker K; Vukelja S; Richards D; Hood J; Coffee K; Nemunaitis J
Mol Ther; 2005 Jan; 11(1):149-59. PubMed ID: 15585416
[TBL] [Abstract][Full Text] [Related]
19. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.
Cornett WR; McCall LM; Petersen RP; Ross MI; Briele HA; Noyes RD; Sussman JJ; Kraybill WG; Kane JM; Alexander HR; Lee JE; Mansfield PF; Pingpank JF; Winchester DJ; White RL; Chadaram V; Herndon JE; Fraker DL; Tyler DS;
J Clin Oncol; 2006 Sep; 24(25):4196-201. PubMed ID: 16943537
[TBL] [Abstract][Full Text] [Related]
20. Inflammation-inducible anti-TNF gene expression mediated by intra-articular injection of serotype 5 adeno-associated virus reduces arthritis.
Khoury M; Adriaansen J; Vervoordeldonk MJ; Gould D; Chernajovsky Y; Bigey P; Bloquel C; Scherman D; Tak PP; Jorgensen C; Apparailly F
J Gene Med; 2007 Jul; 9(7):596-604. PubMed ID: 17514770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
